why choose us

Clinical Trials Search

Showing 15,140 of 132,656 result(s)
Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer

Status: Completed

Condition: Prostate Cancer

Interventions: Apalutamide 240 mg by mouth daily for a total of 6-months.

Date: 2023-02-07

Trigeminal Evoked Responses to Improve Rhizotomy

Status: Completed

Condition: Trigeminal Neuralgia

Interventions: TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery.
TSEPs will be measured at baseline prior to surg

Date: 2023-02-07

Achieving Diagnostic Excellence Through Prevention and Teamwork

Status: NOT_YET_RECRUITING

Condition: Diagnostic Errors

Interventions: Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality a

Date: 2023-02-07

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Status: Completed

Condition: Psoriasis

Interventions: Specified dose on specified days

Date: 2023-02-07

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Status: Completed

Condition: Small Cell Lung Cancer (SCLC)

Interventions: Tarlatamab will be administered as an IV infusion.

Date: 2023-02-07

rTMS and Rehabilitation for Individuals With CRPS Type 1

Status: Completed

Condition: Complex Regional Pain Syndrome Type I

Interventions: rTMS will be delivered using a commercially available magnetic stimulator (Rapid2, Magstim Inc., Eden Prairie, MN) with a figure-of-8 Air Film coil at

Date: 2023-02-07

A Study of TL-925 as a Treatment for Dry Eye Disease

Status: COMPLETED

Condition: Dry Eye Disease

Interventions: TL-925 is an eye drop.

Date: 2023-02-07

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Status: Completed

Condition: Newly Diagnosed MGMT Unmethylated Glioblastoma

Interventions: D2C7-IT will be dosed at 166,075 ng in 36 mL.

Date: 2023-02-07

Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Status: Completed

Condition: Locally Advanced Basal Cell Carcinoma

Interventions: Given IV

Date: 2023-02-07

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

Status: COMPLETED

Condition: Healthy Volunteer

Interventions: Single Oral Dose - Tablet

Date: 2023-02-07